Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial | Zendy

Linda BarlowMosha | Zendy; Konstantia Angelidou | Zendy; Jane C. Lindsey | Zendy; Moherndran Archary | Zendy; Mark F. Cotton | Zendy; Sylvia Dittmer | Zendy; Lee Fairlie | Zendy; Enid Kabugho | Zendy; Portia Kamthunzi | Zendy; Arti Kinikar | Zendy; Tapiwa Mbengeranwa | Zendy; Levina Msuya | Zendy; Pauline Sambo | Zendy; Kunjal Patel | Zendy; Emily Barr | Zendy; Patrick Jean-Phillipe | Zendy; Avy Violari | Zendy; Lynne Mofenson | Zendy; Paul Palumbo | Zendy; H. Benjamin | Zendy

Open Access

Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial

Author(s) -

Linda BarlowMosha,

Konstantia Angelidou,

Jane C. Lindsey,

Moherndran Archary,

Mark F. Cotton,

Sylvia Dittmer,

Lee Fairlie,

Enid Kabugho,

Portia Kamthunzi,

Arti Kinikar,

Tapiwa Mbengeranwa,

Levina Msuya,

Pauline Sambo,

Kunjal Patel,

Emily Barr,

Patrick Jean-Phillipe,

Avy Violari,

Lynne Mofenson,

Paul Palumbo,

H. Benjamin

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw488

Subject(s) - nevirapine , lopinavir , ritonavir , lopinavir/ritonavir , medicine , antiretroviral therapy , pediatrics , randomized controlled trial , clinical trial , human immunodeficiency virus (hiv) , viral load , virology

The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1060 study demonstrated short-term superiority of lopinavir/ritonavir (LPV/r) over nevirapine (NVP) in antiretroviral therapy (ART), regardless of prior NVP exposure. However, NVP-based ART had a marginal benefit in CD4 percentage (CD4%) and growth. We compared 5-year outcomes from this clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research